| Literature DB >> 23671078 |
Emilyne Blattes1, Alain Vercellone, Hélène Eutamène, Cédric-Olivier Turrin, Vassilia Théodorou, Jean-Pierre Majoral, Anne-Marie Caminade, Jacques Prandi, Jérôme Nigou, Germain Puzo.
Abstract
Mycobacterium tuberculosis mannose-capped lipoarabinomannan inhibits the release of proinflammatory cytokines by LPS-stimulated human dendritic cells (DCs) via targeting the C-type lectin receptor DC-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN). With the aim of mimicking the bioactive supramolecular structure of mannose-capped lipoarabinomannan, we designed and synthesized a set of poly(phosphorhydrazone) dendrimers grafted with mannose units, called mannodendrimers, that differed by size and the number and length of their (α1→2)-oligommanoside caps. A third-generation dendrimer bearing 48 trimannoside caps (3T) and a fourth-generation dendrimer bearing 96 dimannosides (4D) displayed the highest binding avidity for DC-SIGN. Moreover, these dendrimers inhibited proinflammatory cytokines, including TNF-α, production by LPS-stimulated DCs in a DC-SIGN-dependent fashion. Finally, in a model of acute lung inflammation in which mice were exposed to aerosolized LPS, per os administration of 3T mannodendrimer was found to significantly reduce neutrophil influx via targeting the DC-SIGN murine homolog SIGN-related 1. The 3T mannodendrimer therefore represents an innovative fully synthetic compound for the treatment of lung inflammatory diseases.Entities:
Keywords: ManLAM functional analogs; SIGNR1 targeting; antiinflammatory molecule; glycodendrimer synthesis; multivalent ligands
Mesh:
Substances:
Year: 2013 PMID: 23671078 PMCID: PMC3670345 DOI: 10.1073/pnas.1221708110
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205